CO6541585A2 - Composiciones de lipopétidos y métodos relacionados - Google Patents

Composiciones de lipopétidos y métodos relacionados

Info

Publication number
CO6541585A2
CO6541585A2 CO12097444A CO12097444A CO6541585A2 CO 6541585 A2 CO6541585 A2 CO 6541585A2 CO 12097444 A CO12097444 A CO 12097444A CO 12097444 A CO12097444 A CO 12097444A CO 6541585 A2 CO6541585 A2 CO 6541585A2
Authority
CO
Colombia
Prior art keywords
compositions
lipopeptides
related methods
daptomycin
sucrose
Prior art date
Application number
CO12097444A
Other languages
English (en)
Spanish (es)
Inventor
Sophie Sun
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6541585(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of CO6541585A2 publication Critical patent/CO6541585A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO12097444A 2009-11-23 2012-06-08 Composiciones de lipopétidos y métodos relacionados CO6541585A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
CO6541585A2 true CO6541585A2 (es) 2012-10-16

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12097444A CO6541585A2 (es) 2009-11-23 2012-06-08 Composiciones de lipopétidos y métodos relacionados

Country Status (33)

Country Link
US (3) US8835382B2 (enExample)
EP (2) EP2504353B2 (enExample)
JP (3) JP6041673B2 (enExample)
CN (3) CN104056250A (enExample)
AR (2) AR079127A1 (enExample)
AU (1) AU2010321531C1 (enExample)
BR (1) BR112012012406B1 (enExample)
CA (1) CA2781666C (enExample)
CL (2) CL2012001336A1 (enExample)
CO (1) CO6541585A2 (enExample)
CR (1) CR20120271A (enExample)
CY (1) CY1120854T1 (enExample)
DK (1) DK2504353T4 (enExample)
DO (1) DOP2012000140A (enExample)
EC (1) ECSP12011939A (enExample)
ES (1) ES2686331T5 (enExample)
FI (1) FI2504353T4 (enExample)
HR (1) HRP20181380T4 (enExample)
HU (1) HUE039967T2 (enExample)
IL (1) IL219891B (enExample)
LT (1) LT2504353T (enExample)
MX (1) MX2012005993A (enExample)
NZ (1) NZ600118A (enExample)
PE (2) PE20151717A1 (enExample)
PL (1) PL2504353T5 (enExample)
PT (1) PT2504353T (enExample)
RS (1) RS57566B2 (enExample)
RU (1) RU2607526C2 (enExample)
SG (1) SG10201407724YA (enExample)
SI (1) SI2504353T2 (enExample)
TR (1) TR201812823T4 (enExample)
TW (2) TWI548414B (enExample)
WO (1) WO2011063419A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
DK2504353T4 (da) 2009-11-23 2023-11-20 Cubist Pharmaceuticals Llc Lipopeptidsammensætninger og tilsvarende fremgangsmåder
TW201309346A (zh) 2011-01-05 2013-03-01 Hospira Inc 噴霧乾燥萬古黴素
JP2014515371A (ja) * 2011-05-26 2014-06-30 キュービスト ファーマシューティカルズ, インコーポレイテッド Cb−183,315組成物および関連する方法
CN104168908A (zh) * 2012-01-12 2014-11-26 细胞基因公司 罗米地新制剂及其用途
ES2655215T3 (es) * 2012-08-23 2018-02-19 Mylan Laboratories Ltd. Mejoramiento de la formulación inyectable de daptomicina
US9655946B2 (en) 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
EP3528786B1 (en) 2016-10-21 2023-04-05 Xellia Pharmaceuticals ApS Liquid formulations of daptomycin
JP7229999B2 (ja) * 2017-08-31 2023-02-28 クセリア ファーマシューティカルズ エーピーエス ダプトマイシン製剤
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
CN114828873A (zh) * 2019-12-26 2022-07-29 尼普洛株式会社 含有达托霉素的稳定的冷冻干燥制剂
CN115038431B (zh) 2020-02-28 2024-08-09 埃克斯利亚制药有限公司 达托霉素制剂
CN115243675A (zh) 2020-03-12 2022-10-25 巴克斯特国际公司 含有山梨糖醇和甘露糖醇的组合的达托霉素制剂
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
BG47040A3 (en) 1984-10-09 1990-04-16 Eli Lilly And Company Method for preparing of a- 21978 with cyclic peptidic derivatives
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
EP0386951A3 (en) * 1989-03-06 1992-05-20 Eli Lilly And Company An improved diluent formulation for daptomycin
ES2110405T3 (es) 1990-01-26 1998-02-16 Hoechst Ag Un nuevo antibiotico, desoximulundocandina, un procedimiento para su produccion y su uso como medicamento.
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (enExample) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) * 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
ES2119898T3 (es) 1992-04-20 1998-10-16 Abbott Lab Procedimiento de produccion de vancomicina.
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
SI1115417T1 (sl) 1998-09-25 2006-08-31 Cubist Pharm Inc Uporaba daptomicina
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
KR20020063228A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
PL206492B1 (pl) * 2000-06-21 2010-08-31 Cubist Pharm Inc Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny i jej zastosowania
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重t細胞エピトープポリペプチドの酢酸塩組成物
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
EP1465930B1 (fr) 2002-01-17 2006-05-03 Arkema Polymeres supramoleculaires
EP1578362A4 (en) 2002-07-09 2008-11-05 Point Therapeutics Inc COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−11含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
UA91208C2 (ru) * 2005-02-14 2010-07-12 Венус Ремедиз Лимитед Фармацевтическая композиция, которая содержит антибактериальный гликопептид и цефалоспорин, для терапии резистентных инфекционных состояний
US8003673B2 (en) 2005-05-31 2011-08-23 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
EP1919449A2 (en) 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2008012310A1 (en) * 2006-07-26 2008-01-31 Sandoz Ag Caspofungin formulations
JP5143841B2 (ja) 2006-10-10 2013-02-13 ロス アラモス ナショナル セキュリティー,エルエルシー 高度な薬物開発及び製造
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
CA2687246A1 (en) * 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
CA2692053A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
CN101835508A (zh) * 2007-10-25 2010-09-15 诺瓦提斯公司 单位剂量药物包装的粉末调节
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
DK2504353T4 (da) 2009-11-23 2023-11-20 Cubist Pharmaceuticals Llc Lipopeptidsammensætninger og tilsvarende fremgangsmåder
JP2013511522A (ja) 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
NZ609964A (en) 2010-11-01 2015-08-28 Melinta Therapeutics Inc Pharmaceutical compositions
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルapiローディングプロドラッグ
US20130034597A1 (en) 2011-02-04 2013-02-07 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof

Also Published As

Publication number Publication date
PT2504353T (pt) 2018-10-18
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
RS57566B2 (sr) 2023-12-29
FI2504353T4 (fi) 2023-11-30
DOP2012000140A (es) 2012-10-30
BR112012012406A2 (pt) 2019-12-03
MX2012005993A (es) 2012-11-23
AR079127A1 (es) 2011-12-28
HUE039967T2 (hu) 2019-02-28
TWI548414B (zh) 2016-09-11
CN108785654A (zh) 2018-11-13
AU2010321531C1 (en) 2020-10-01
AU2010321531B2 (en) 2016-11-03
PL2504353T3 (pl) 2018-11-30
PL2504353T5 (pl) 2023-11-20
US20160030577A1 (en) 2016-02-04
HRP20181380T1 (hr) 2018-10-19
SI2504353T2 (sl) 2023-11-30
CA2781666C (en) 2017-02-21
PE20151717A1 (es) 2015-11-19
NZ600118A (en) 2014-08-29
CL2015002412A1 (es) 2016-02-05
US20140364380A1 (en) 2014-12-11
CN102712677B (zh) 2015-06-03
AU2010321531A2 (en) 2014-10-30
EP2504353A2 (en) 2012-10-03
IL219891A0 (en) 2012-07-31
EP2504353A4 (en) 2014-04-02
TW201703791A (zh) 2017-02-01
HRP20181380T4 (hr) 2023-11-10
PE20121517A1 (es) 2012-11-26
WO2011063419A3 (en) 2011-10-13
SI2504353T1 (sl) 2018-10-30
IL219891B (en) 2018-01-31
RS57566B1 (sr) 2018-10-31
CR20120271A (es) 2012-08-01
AU2010321531A1 (en) 2012-06-14
EP3417849A1 (en) 2018-12-26
ECSP12011939A (es) 2012-07-31
EP2504353B1 (en) 2018-07-11
JP2016147874A (ja) 2016-08-18
JP6041673B2 (ja) 2016-12-14
LT2504353T (lt) 2018-09-25
CN104056250A (zh) 2014-09-24
DK2504353T3 (en) 2018-09-10
SG10201407724YA (en) 2014-12-30
US20120270772A1 (en) 2012-10-25
CN102712677A (zh) 2012-10-03
AR123846A2 (es) 2023-01-18
BR112012012406B1 (pt) 2021-11-16
JP6239167B2 (ja) 2017-11-29
TR201812823T4 (tr) 2019-02-21
ES2686331T5 (es) 2024-03-27
ES2686331T3 (es) 2018-10-17
JP6088681B2 (ja) 2017-03-01
CA2781666A1 (en) 2011-05-26
RU2012126076A (ru) 2013-12-27
US9662397B2 (en) 2017-05-30
EP2504353B2 (en) 2023-09-13
RU2607526C2 (ru) 2017-01-10
CY1120854T1 (el) 2019-12-11
US9138456B2 (en) 2015-09-22
CL2012001336A1 (es) 2012-10-05
US8835382B2 (en) 2014-09-16
JP2013511557A (ja) 2013-04-04
WO2011063419A2 (en) 2011-05-26
DK2504353T4 (da) 2023-11-20
JP2017075186A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
CO6541585A2 (es) Composiciones de lipopétidos y métodos relacionados
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
MX2013003365A (es) Composicion farmaceutica.
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
EP4403197A3 (en) Injectable formulations for organ augmentation
ECSP12012031A (es) Composición farmacéutica que comprende oligopéptidos
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
CR11772A (es) Metodos y composicion liquidas de limpieza
EA201391523A1 (ru) Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток
BR112012019997A2 (pt) composições de cuidado oral
NZ741342A (en) Daptomycin formulations and uses thereof
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
IN2012DN03404A (enExample)
BR112015028824A2 (pt) composição de tensoativo concentrada
UY33208A (es) Composiciones que comprenden productos de azúcar cisteína
BR112012004916A2 (pt) composições sns-595 estáveis e métodos de preparação
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
IN2015DN04074A (enExample)
WO2012138731A3 (en) Activated nucleoside analog conjugates and methods of use thereof
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.